CU24091B1 - Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden - Google Patents
Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprendenInfo
- Publication number
- CU24091B1 CU24091B1 CU2012000015A CU20120015A CU24091B1 CU 24091 B1 CU24091 B1 CU 24091B1 CU 2012000015 A CU2012000015 A CU 2012000015A CU 20120015 A CU20120015 A CU 20120015A CU 24091 B1 CU24091 B1 CU 24091B1
- Authority
- CU
- Cuba
- Prior art keywords
- cdk9
- piridin
- piridine
- salts
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- AIDS & HIV (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
Abstract
La presente invención proporciona un compuesto de la fórmula (I): ESPACIO PARA LA FÓRMULA y las sales farmacéuticamente aceptables, enantiómeros, estereoisómeros, rotámeros, tautómeros, diaestereómeros, o racematos del mismo. También se proporciona un método para el tratamiento de una enfermedad o condición mediada por CDK9.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27315409P | 2009-07-30 | 2009-07-30 | |
US35772010P | 2010-06-23 | 2010-06-23 | |
PCT/EP2010/060984 WO2011012661A1 (en) | 2009-07-30 | 2010-07-28 | Pyridine and pyrazine derivatives as protein kinase modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
CU20120015A7 CU20120015A7 (es) | 2012-04-15 |
CU24091B1 true CU24091B1 (es) | 2015-04-29 |
Family
ID=42727614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2012000015A CU24091B1 (es) | 2009-07-30 | 2010-07-28 | Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden |
Country Status (31)
Country | Link |
---|---|
US (3) | US8415381B2 (es) |
EP (1) | EP2459535B1 (es) |
JP (2) | JP5650735B2 (es) |
KR (1) | KR101464052B1 (es) |
CN (1) | CN102482218B (es) |
AR (1) | AR077505A1 (es) |
AU (1) | AU2010277588B2 (es) |
BR (1) | BR112012008074A2 (es) |
CA (1) | CA2767066A1 (es) |
CL (1) | CL2012000092A1 (es) |
CO (1) | CO6612188A2 (es) |
CR (1) | CR20120051A (es) |
CU (1) | CU24091B1 (es) |
DO (1) | DOP2012000025A (es) |
EA (1) | EA023561B1 (es) |
EC (1) | ECSP12011638A (es) |
ES (1) | ES2536479T3 (es) |
GE (1) | GEP20146101B (es) |
GT (1) | GT201200022A (es) |
IL (2) | IL217524A0 (es) |
MA (1) | MA33540B1 (es) |
MX (1) | MX2012001281A (es) |
MY (1) | MY183373A (es) |
NI (1) | NI201200016A (es) |
NZ (1) | NZ597551A (es) |
PE (1) | PE20121127A1 (es) |
SG (1) | SG177660A1 (es) |
TW (1) | TW201107307A (es) |
UY (1) | UY32810A (es) |
WO (1) | WO2011012661A1 (es) |
ZA (1) | ZA201109166B (es) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8354411B2 (en) | 2009-02-05 | 2013-01-15 | Takeda Pharmaceutical Company Limited | 1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound |
US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
US9242937B2 (en) | 2011-03-02 | 2016-01-26 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted pyridine derivatives |
US9226929B2 (en) | 2011-03-02 | 2016-01-05 | Bayer Intellectual Property Gmbh | Pharmaceutically active disubstituted triazine derivatives |
US8916557B2 (en) * | 2011-04-19 | 2014-12-23 | Bayer Intellectual Property Gmbh | Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines |
EP2527332A1 (en) | 2011-05-24 | 2012-11-28 | Bayer Intellectual Property GmbH | 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors |
TWI555737B (zh) * | 2011-05-24 | 2016-11-01 | 拜耳知識產權公司 | 含有硫醯亞胺基團之4-芳基-n-苯基-1,3,5-三氮雜苯-2-胺 |
EP2561867A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
EP2562265A1 (en) | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | Susceptibility to selective CDK9 inhibitors |
WO2013037894A1 (en) | 2011-09-16 | 2013-03-21 | Bayer Intellectual Property Gmbh | Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group |
JP5982490B2 (ja) | 2011-09-16 | 2016-08-31 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 二置換5−フルオロ−ピリミジン |
WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
CN105283453B (zh) | 2012-10-18 | 2018-06-22 | 拜耳药业股份公司 | 含砜基的n-(吡啶-2-基)嘧啶-4-胺衍生物 |
EP2909183B1 (en) | 2012-10-18 | 2016-08-24 | Bayer Pharma Aktiengesellschaft | 4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfone group |
EP2909176B1 (en) | 2012-10-18 | 2016-07-20 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
NZ707084A (en) | 2012-11-15 | 2019-09-27 | Bayer Pharma AG | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group |
TW201418243A (zh) | 2012-11-15 | 2014-05-16 | Bayer Pharma AG | 含有磺醯亞胺基團之n-(吡啶-2-基)嘧啶-4-胺衍生物 |
ES2630115T3 (es) | 2013-07-04 | 2017-08-18 | Bayer Pharma Aktiengesellschaft | Derivados de 5-fluoro-n-(piridin-2-il)piridin-2-amina con sulfoximina sustituida y su uso como inhibidores de quinasa cdk9 |
CA2942119A1 (en) | 2014-03-13 | 2015-09-17 | Bayer Pharma Aktiengesellschaft | 5-fluoro-n-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group |
CN106414412B (zh) | 2014-04-01 | 2019-06-21 | 拜耳医药股份有限公司 | 含有磺酰二亚胺基团的二取代的5-氟嘧啶衍生物 |
AU2015243585B2 (en) | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
JO3589B1 (ar) | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
CA3000633C (en) | 2014-10-14 | 2023-10-03 | The Regents Of The University Of California | Use of cdk9 and brd4 inhibitors to inhibit inflammation |
CA2964696C (en) | 2014-10-16 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group |
JP2017531003A (ja) | 2014-10-16 | 2017-10-19 | バイエル ファーマ アクチエンゲゼルシャフト | スルホン基を含有するフッ化ベンゾフラニル−ピリミジン誘導体 |
US20180078560A1 (en) | 2015-03-24 | 2018-03-22 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating multiple myeloma |
EP3273963A1 (en) | 2015-03-24 | 2018-01-31 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating lymphomas |
WO2016150902A1 (en) | 2015-03-24 | 2016-09-29 | Bayer Pharma Aktiengesellschaft | Use of 4-(4-fluoro-2-methoxyphenyl)-n-{3-[(s-methylsulfonimidoyl)methyl]phenyl}-1,3,5-triazin-2-amine for treating gastric cancers |
EP3319959B1 (en) | 2015-07-06 | 2021-09-01 | Alkermes, Inc. | Hetero-halo inhibitors of histone deacetylase |
EP3319968A1 (en) | 2015-07-06 | 2018-05-16 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
ES2786552T3 (es) | 2015-09-29 | 2020-10-13 | Bayer Pharma AG | Compuestos de sulfondiimina macrocíclicos nuevos |
JP6888000B2 (ja) | 2015-10-08 | 2021-06-16 | バイエル ファーマ アクチエンゲゼルシャフト | 新規な修飾された大環状化合物 |
WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
PT3380465T (pt) | 2015-11-26 | 2020-10-23 | Novartis Ag | Derivados de diamino piridina |
WO2018132531A1 (en) | 2017-01-11 | 2018-07-19 | Rodin Therapeutics, Inc. | Bicyclic inhibitors of histone deacetylase |
EP3601236A1 (en) | 2017-03-28 | 2020-02-05 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
WO2018177899A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
SG11202000970WA (en) | 2017-08-07 | 2020-02-27 | Rodin Therapeutics Inc | Bicyclic inhibitors of histone deacetylase |
MX2020008447A (es) | 2018-02-13 | 2020-09-28 | Bayer Ag | Uso de 5-fluoro-4-(4-fluoro-2-metoxifenil)-n-{4-[(s-metilsulfonimi doil)metil]piridin-2-il}piridin-2-amina para el tratamiento del linfoma difuso de celulas grandes b. |
KR20200138306A (ko) | 2018-03-29 | 2020-12-09 | 다케다 야쿠힌 고교 가부시키가이샤 | 헤테로시클릭 화합물 |
EP3790867B1 (en) | 2018-05-11 | 2024-03-27 | Imago Biosciences Inc. | Kdm1a inhibitors for the treatment of disease |
RU2754441C2 (ru) * | 2019-12-30 | 2021-09-02 | Закрытое Акционерное Общество "Биокад" | Новые ингибиторы cdk8/19 |
BR112022023199A2 (pt) | 2020-05-15 | 2023-04-04 | Algen Biotechnologies Inc | Certas composições químicas e métodos de uso das mesmas |
WO2022199654A1 (en) * | 2021-03-24 | 2022-09-29 | Chengdu Anticancer Bioscience, Ltd. | Heteroaryl-heteroaryl-o-phenyl compounds, compositions and methods of treating cancer disorders |
CN114098838B (zh) * | 2021-11-12 | 2022-05-31 | 北京中研智创新技术研究院有限公司 | 一种可定向弯曲的用于提取脑组织病变的活检针套件 |
WO2023225601A2 (en) * | 2022-05-18 | 2023-11-23 | Trustees Of Tufts College | Ripk2 and nod inhibitors |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4031798A1 (de) | 1990-10-08 | 1992-04-09 | Hoechst Ag | Pyridylpyrimidine, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide |
JPH0995489A (ja) * | 1995-07-26 | 1997-04-08 | Hokko Chem Ind Co Ltd | イソニコチン酸誘導体および農園芸用殺菌剤 |
CA2423050A1 (en) * | 2000-09-20 | 2002-03-28 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
AU2001289588A1 (en) | 2000-09-25 | 2002-04-02 | Novozymes A/S | Phospholipase from zygoascus hellenicus |
JP4901102B2 (ja) * | 2002-05-03 | 2012-03-21 | エクセリクシス, インク. | プロテインキナーゼモジュレーターおよびその使用方法 |
DK2256108T3 (en) | 2002-07-18 | 2016-04-11 | Janssen Pharmaceutica Nv | Substituted triazinkinaseinhibitorer |
CA2496197A1 (en) * | 2002-08-20 | 2004-03-04 | Neurogen Corporation | 5-substituted-2-arylpyrazines as modulators of crf receptors |
SE0203654D0 (sv) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
JP4867350B2 (ja) | 2003-12-19 | 2012-02-01 | 宇部興産株式会社 | 4−置換−4−シアノテトラヒドロピラン化合物の製法 |
AU2005232745A1 (en) | 2004-04-13 | 2005-10-27 | Astellas Pharma Inc. | Polycyclic pyrimidines as potassium ion channel modulators |
EP2094682A2 (en) | 2006-12-22 | 2009-09-02 | Novartis AG | Heteroaryl-heteroaryl compounds as cdk inhibitors for the treatment of cancer, inflammation and viral infections |
EP2132177B1 (en) * | 2007-03-01 | 2013-07-17 | Novartis AG | Pim kinase inhibitors and methods of their use |
EP2164840A2 (en) * | 2007-05-09 | 2010-03-24 | Vertex Pharmaceuticals Incorporated | Modulators of cftr |
EP2178537A4 (en) | 2007-07-19 | 2011-08-17 | Merck Sharp & Dohme | BETA-CARBOLIN DERIVATIVES AS ANTIDIBLE COMPOUNDS |
US8507488B2 (en) * | 2008-05-13 | 2013-08-13 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
AU2009256574A1 (en) * | 2008-06-13 | 2009-12-17 | Novartis Ag | 2,4'-bipyridinyl compounds as protein kinase D inhibitors useful for the treatment of IA heart failure and cancer |
CA3013000C (en) | 2008-12-19 | 2022-12-13 | Vertex Pharmaceuticals Incorporated | Pyrazine derivatives useful as inhibitors of atr kinase |
US8415381B2 (en) * | 2009-07-30 | 2013-04-09 | Novartis Ag | Heteroaryl compounds and their uses |
KR20120076352A (ko) * | 2009-09-04 | 2012-07-09 | 노파르티스 아게 | 증식성 질환의 치료에 유용한 피라지닐피리딘 |
AU2010291206A1 (en) * | 2009-09-04 | 2012-02-23 | Novartis Ag | Bipyridines useful for the treatment of proliferative diseases |
CN103339110A (zh) * | 2011-01-28 | 2013-10-02 | 诺瓦提斯公司 | 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途 |
-
2010
- 2010-07-26 US US12/843,494 patent/US8415381B2/en not_active Expired - Fee Related
- 2010-07-28 MX MX2012001281A patent/MX2012001281A/es active IP Right Grant
- 2010-07-28 MY MYPI2012000154A patent/MY183373A/en unknown
- 2010-07-28 EA EA201200209A patent/EA023561B1/ru not_active IP Right Cessation
- 2010-07-28 CU CU2012000015A patent/CU24091B1/es not_active IP Right Cessation
- 2010-07-28 ES ES10736734.4T patent/ES2536479T3/es active Active
- 2010-07-28 SG SG2012002770A patent/SG177660A1/en unknown
- 2010-07-28 PE PE2012000119A patent/PE20121127A1/es not_active Application Discontinuation
- 2010-07-28 EP EP10736734.4A patent/EP2459535B1/en active Active
- 2010-07-28 AU AU2010277588A patent/AU2010277588B2/en not_active Ceased
- 2010-07-28 BR BR112012008074A patent/BR112012008074A2/pt not_active IP Right Cessation
- 2010-07-28 AR ARP100102732A patent/AR077505A1/es unknown
- 2010-07-28 CN CN201080033688.3A patent/CN102482218B/zh not_active Expired - Fee Related
- 2010-07-28 WO PCT/EP2010/060984 patent/WO2011012661A1/en active Application Filing
- 2010-07-28 JP JP2012522168A patent/JP5650735B2/ja not_active Expired - Fee Related
- 2010-07-28 CA CA2767066A patent/CA2767066A1/en not_active Abandoned
- 2010-07-28 NZ NZ597551A patent/NZ597551A/xx not_active IP Right Cessation
- 2010-07-28 KR KR1020127005200A patent/KR101464052B1/ko not_active IP Right Cessation
- 2010-07-28 GE GEAP201012602A patent/GEP20146101B/en unknown
- 2010-07-29 TW TW099125158A patent/TW201107307A/zh unknown
- 2010-07-29 UY UY0001032810A patent/UY32810A/es not_active Application Discontinuation
-
2011
- 2011-12-13 ZA ZA2011/09166A patent/ZA201109166B/en unknown
-
2012
- 2012-01-12 CL CL2012000092A patent/CL2012000092A1/es unknown
- 2012-01-12 IL IL217524A patent/IL217524A0/en unknown
- 2012-01-27 DO DO2012000025A patent/DOP2012000025A/es unknown
- 2012-01-27 NI NI201200016A patent/NI201200016A/es unknown
- 2012-01-27 GT GT201200022A patent/GT201200022A/es unknown
- 2012-01-30 CR CR20120051A patent/CR20120051A/es unknown
- 2012-01-30 EC EC2012011638A patent/ECSP12011638A/es unknown
- 2012-02-09 CO CO12023085A patent/CO6612188A2/es active IP Right Grant
- 2012-02-27 MA MA34654A patent/MA33540B1/fr unknown
-
2013
- 2013-02-21 US US13/773,052 patent/US8778951B2/en not_active Expired - Fee Related
-
2014
- 2014-06-04 US US14/295,398 patent/US20140288076A1/en not_active Abandoned
- 2014-06-09 IL IL233040A patent/IL233040A0/en unknown
- 2014-11-13 JP JP2014230877A patent/JP2015052005A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU24091B1 (es) | Derivados de 2-(piridin-4-il)piridina o sales de los mismos como moduladores de proteína quinasa cdk9 y composiciones farmacéuticas que los comprenden | |
CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
UY32848A (es) | Compuestos heterocíclicos de oxima | |
EA201390717A1 (ru) | 3-(аминоарил)пиридиновые соединения | |
CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
SV2016005137A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
BR112016016844A2 (pt) | Compostos heterocíclicos | |
UY32640A (es) | Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona | |
GT201300174A (es) | Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme) | |
CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
CO6400220A2 (es) | Derivados de sulfonamida | |
ECSP11011306A (es) | Derivados de benzofuranilo | |
CO6460766A2 (es) | Compuestos de haloalquil heteroaril benzamida | |
CO6491060A2 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
UY30267A1 (es) | Nuevos derivados de la tioxantina , composiciones farmacéuticas que los contienen, procedimientos de preparacion y aplicaciones | |
CU20160192A7 (es) | Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble | |
UY33075A (es) | Derivados de ciclohexano y usos de los mismos | |
CR10573A (es) | Derivados del pirazol como inhibidores del citocromo p450 | |
UY30835A1 (es) | 8-alquinilxantinas y derivados | |
CR20130530A (es) | Derivados glucósidos y sus usos para el tratamiento de la diabetes | |
CO6361924A2 (es) | Nuevas lactamas como inhibidores de beta secretasa | |
UY35419A (es) | Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant of patent | ||
FD | Lapse (for not paying fees) |